Anti-Nectin-4 (Enfortumab Vedotin), Human IgG1 Antibody

• Data sheet: View or download

The research-grade biosimilar is an antibody-drug conjugate that targets Nectin-4, which is highly expressed in urothelial cancers. The original conjugate comprises an anti-Nectin-4 human monoclonal antibody that is chemically linked to a microtubule disrupting drug, monomethyl auristatin E (MMAE) via a protease-cleavable linker. Upon internalization in the cell, the MMAE is detached from the antibody due to proteolytic cleavage. The MMAE then disrupts the microtubule network, arrests cell cycle, and induces apoptosis. The original drug conjugate is approved by the FDA to treat metastatic bladder cancer patients, who were previously treated with platinum-containing chemotherapy, or PD-1/PD-L1 checkpoint inhibitors